Wow, guess I'm in the minority in that I appreciate that Dan has shed some light on some risks and concerns relating to Kevetrin that had not previously been brightly illuminated on this board.
While I'm long CTIX, and hold out great hope that both Kevetrin and Prurisol will develop into true blockbusters - I do not believe in blind faith. I am eager to evaluate with as critical an eye as possible the portfolio of compounds on which this company's future (and my investment dollars) are dependent.
Regardless of whatever bias (or agenda) Dan may have for his postings, this does not make the factual content of his posts any less real or legitimate.
Perhaps part of the attack against him and his posts is a kind of a shoot the messenger thing going on? A kind of textbook exhibit of cognitive dissonance - where exposure to facts that challenge deeply entrenched beliefs and assumptions is so painful, that people will react irrationally in order to avoid exposure ( i.e., the earth is flat).
Dan has helped to tamp down my pie in the sky expectations for K's success. Still think the upside is unlimited, but now more informed about the unknowns that could derail such success. I will not sell a share as a result, and plan on buying more in the future, but maybe will be a bit more patient on waiting for more resolution as to those unknowns before doing so (even if it costs me a few more shekels)...
News 
Market Data 
Discover 
AI
